AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4919118 — intervention group
Group type: COMPARATOR
Intervention: Pancrex V forte
Number of subjects: 12
Study 4919118 — intervention group
Group type: COMPARATOR
Intervention: Nutrizym core alone
Number of subjects: 12
Study 30971173 — intervention group
Group type: EXPERIMENTAL
Intervention: A-FFIP intervention (2 hours/week)
Number of subjects: 20
Study 30971173 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 20
Study 30403428 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions (ECC)
Number of subjects: 14
Study 30403428 — intervention group
Group type: COMPARATOR
Intervention: Concentric contractions (CON)
Number of subjects: 14
Study 28011798 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis with ECG recording based on levels; participants with NT-proBNP ≤ 125 pg/L will have a single one lead ECG recording, and those with NT-proBNP ≥ 125 pg/L will record ECG for 30 seconds at least twice daily for 2 weeks.
Number of subjects: 28712
Study 28011798 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard care without screening.
Number of subjects: 28712
Study 28844541 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8852 (250, 750, 1,500, or 3000 mg)
Number of subjects: 40
Study 28844541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28844541 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8852 (750 mg and 3000 mg)
Number of subjects: 40
Study 23504050 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mcg IFNB‐1b
Number of subjects: 0
Study 21521860 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic levetiracetam formulations
Number of subjects: 4
Study 21521860 — intervention group
Group type: COMPARATOR
Intervention: Keppra (brand name levetiracetam)
Number of subjects: 4
Study 19745646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics (neuroleptics and atypicals)
Number of subjects: 20
Study 19745646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17928597 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg per square meter) after doxorubicin plus cyclophosphamide
Number of subjects: 1500
Study 17928597 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60, 75, or 90 mg per square meter) plus cyclophosphamide (600 mg per square meter)
Number of subjects: 1500
Study 17928597 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group) after doxorubicin plus cyclophosphamide
Number of subjects: 1500
Study 15519779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucralfate (3 g suspension, twice daily)
Number of subjects: 298
Study 15519779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 11681650 — intervention group
Group type: EXPERIMENTAL
Intervention: AERx (0.45 mg total)
Number of subjects: 4
Study 11681650 — intervention group
Group type: COMPARATOR
Intervention: PARI (3.0 mg nebulized until dry)
Number of subjects: 4
Study 11681650 — intervention group
Group type: EXPERIMENTAL
Intervention: AERx
Number of subjects: 4
Study 9627590 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines (two three-component vaccines)
Number of subjects: 1572
Study 9627590 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine
Number of subjects: 1572
Study 7836714 — intervention group
Group type: COMPARATOR
Intervention: Contractors
Number of subjects: 250
Study 7836714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocontractors
Number of subjects: 250
Study 7836714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone volume
Number of subjects: 250
Study 7836714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (0.1 nM-1 microM)
Number of subjects: 250
Study 2971233 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the sacroiliac joint (Experimental Group, n = 10)
Number of subjects: 26
Study 2971233 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group, n = 10)
Number of subjects: 26
Study 29196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus IP 174178 (Lc)
Number of subjects: 98
Study 29196153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26771781 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine 200 mg twice daily for 7 days
Number of subjects: 88
Study 26771781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25015597 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water (n = 158)
Number of subjects: 328
Study 25015597 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (n = 162)
Number of subjects: 328
Study 23510945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis alert to Attending Physician before discharge
Number of subjects: 2513
Study 23510945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alert)
Number of subjects: 2513
Study 23510945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis alert group
Number of subjects: 2513
Study 23510945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2513
Study 20466437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg eicosapentaenoic acid (EPA)
Number of subjects: 42
Study 20466437 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 42
Study 20466437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg eicosapentaenoic acid (EPA) + 20 mg fluoxetine
Number of subjects: 42
Study 20466437 — intervention group
Group type: COMPARATOR
Intervention: 20 mg fluoxetine (control)
Number of subjects: 42
Study 19093917 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention (individualized session with supportive phone calls every 4 months for 2 years and annual lectures on physical activity)
Number of subjects: 632
Study 19093917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 632
Study 16613927 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 54
Study 16613927 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 54
Study 15562739 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic leather mask
Number of subjects: 900
Study 15562739 — intervention group
Group type: COMPARATOR
Intervention: Adhesive tape
Number of subjects: 900
Study 15562739 — intervention group
Group type: COMPARATOR
Intervention: Cotton band
Number of subjects: 900
Study 11113686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone at 30 mg/day
Number of subjects: 45
Study 11113686 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide at 5 mg/day
Number of subjects: 45
Study 11113686 — intervention group
Group type: COMPARATOR
Intervention: Voglibose at 0.6 mg/day
Number of subjects: 45
Study 8669673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 0.5% bupivacaine (2-4 ml)
Number of subjects: 11
Study 8669673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-cold lactated Ringer's solution administered intravenously before spinal blockade
Number of subjects: 11
Study 7952483 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (200 mg/kg) administered before cardiopulmonary bypass and on the first and second postoperative days
Number of subjects: 10
Study 7952483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same volume as glutathione)
Number of subjects: 10
Study 3111931 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 2 X 400 micrograms
Number of subjects: 300
Study 3111931 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 2 X 200 micrograms
Number of subjects: 300
Study 3111931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 31099474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% q8h
Number of subjects: 10
Study 31099474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brinzolamide 1% q8h
Number of subjects: 10
Study 31099474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% q12h combined with dorzolamide
Number of subjects: 10
Study 31099474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% q12h combined with brinzolamide
Number of subjects: 10
Study 31099474 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol 0.5% q12h
Number of subjects: 10
Study 29579490 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT program (psychosocial intervention)
Number of subjects: 34
Study 28167482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50mg twice a day for twelve weeks
Number of subjects: 70
Study 28167482 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850mg twice a day for twelve weeks
Number of subjects: 70
Study 28167482 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 70
Study 23633187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administered before skin incision
Number of subjects: 65
Study 23633187 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotics administered after obtaining operative cultures
Number of subjects: 65
Study 23108892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1,250 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 58
Study 23108892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus Gemcitabine (Gem)
Number of subjects: 58
Study 21960587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (annual treatment)
Number of subjects: 216
Study 21960587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard first-line ITP therapy
Number of subjects: 216
Study 21960587 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving patients post-ITP treatment
Number of subjects: 216
Study 21960587 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring plan for ITP
Number of subjects: 216
Study 18926826 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/d
Number of subjects: 48
Study 18926826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (62% energy restriction for 2 days)
Number of subjects: 35
Study 16855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum food intake after energy restriction
Number of subjects: 35
Study 14648409 — intervention group
Group type: EXPERIMENTAL
Intervention: DoubleLayer stent (DLS)
Number of subjects: 120
Study 14648409 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene stent (PE)
Number of subjects: 120
Study 10802775 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (1.0, 2.5, or 7.5 mg orally daily)
Number of subjects: 715
Study 10802775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study 8835114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP)
Number of subjects: 0
Study 8835114 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP)
Number of subjects: 0
Study 1362436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% dapiprazole
Number of subjects: 20
Study 1362436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3095410 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline)
Number of subjects: 12
Study 3095410 — intervention group
Group type: COMPARATOR
Intervention: Control solution (isotonic saline, 0.9% w/v)
Number of subjects: 12
Study 3095410 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline) in nonatopic control subjects
Number of subjects: 12
Study 3095410 — intervention group
Group type: COMPARATOR
Intervention: Control solution (isotonic saline, 0.9% w/v) in nonatopic control subjects
Number of subjects: 12
Study 29294930 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingman 101 program
Number of subjects: 80
Study 29294930 — intervention group
Group type: COMPARATOR
Intervention: No-program control condition
Number of subjects: 80
Study 30715932 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Controlled Local Anesthetic Device (CCLAD) in upright position
Number of subjects: 110
Study 30715932 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Controlled Local Anesthetic Device (CCLAD) in supine position
Number of subjects: 110
Study 30715932 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe (compared to CCLAD)
Number of subjects: 110
Study 27417903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 2180
Study 27417903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (stopping CTX)
Number of subjects: 2180
Study 24509190 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1057
Study 24509190 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1057
Study 22885014 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine administered sequentially 21 days before first dose (N=73)
Number of subjects: 313
Study 22885014 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine administered sequentially 21 days after second dose (N=72)
Number of subjects: 313
Study 22885014 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine co-administered first dose (N=84)
Number of subjects: 313
Study 22885014 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine co-administered second dose (N=84)
Number of subjects: 313
Study 22885014 — intervention group
Group type: COMPARATOR
Intervention: Trivalent seasonal influenza vaccine (TIV)
Number of subjects: 313
Study 19782973 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) method with injected hydrostatic pressure after thawing
Number of subjects: 0
Study 19782973 — intervention group
Group type: COMPARATOR
Intervention: No assisted hatching (control group)
Number of subjects: 0
Study 18248643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (1500 mg/day orally)
Number of subjects: 14
Study 18248643 — intervention group
Group type: COMPARATOR
Intervention: Ghrelin injection
Number of subjects: 14
Study 18248643 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 14
Study 18248643 — intervention group
Group type: COMPARATOR
Intervention: Baseline NPY levels
Number of subjects: 14
Study 16277714 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scoring errors
Number of subjects: 56
Study 16277714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer reliability
Number of subjects: 56
Study 16277714 — intervention group
Group type: EXPERIMENTAL
Intervention: AP2 score misclassification
Number of subjects: 56
Study 16277714 — intervention group
Group type: EXPERIMENTAL
Intervention: AP2 score cut-off of 25
Number of subjects: 56
Study 12610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after acute smoking (smokers smoked three cigarettes immediately before insulin administration)
Number of subjects: 43
Study 12610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after nonacute smoking (smokers had not smoked since midnight)
Number of subjects: 43
Study 12610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after acute smoking (smokers)
Number of subjects: 43
Study 12610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after nonacute smoking (smokers)
Number of subjects: 43
Study 12610021 — intervention group
Group type: COMPARATOR
Intervention: Inhaled insulin (33.8 IU) administered to nonsmokers
Number of subjects: 43
Study 12610021 — intervention group
Group type: COMPARATOR
Intervention: Inhaled insulin (33.8 IU) administered to smokers
Number of subjects: 43
Study 10726229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of polyethylene glycol solutions
Number of subjects: 30
Study 10726229 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of polyethylene glycol
Number of subjects: 30
Study 10726229 — intervention group
Group type: EXPERIMENTAL
Intervention: Three administrations of polyethylene glycol in a three‐day period
Number of subjects: 30
Study 7731143 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 0
Study 7731143 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg/day
Number of subjects: 0
Study 7731143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1664106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashish (200 mg hashish with 11.5% THC per 1 g tobacco cigarette)
Number of subjects: 48
Study 1664106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7005872 — intervention group
Group type: EXPERIMENTAL
Intervention: nicergoline 30 mg/day divided into 6 doses
Number of subjects: 28
Study 7005872 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 31732300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianhuaqingwen (LHQW) granules
Number of subjects: 140
Study 31732300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31181266 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economic tools/processes
Number of subjects: 0
Study 31181266 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28466396 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling practices by pharmacists
Number of subjects: 129
Study 26062192 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgaleal acupoint injection with metoclopramide
Number of subjects: 64
Study 26062192 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of flunarizine (2.5 mg each time, once every night for 3 months)
Number of subjects: 64
Study 22431239 — intervention group
Group type: EXPERIMENTAL
Intervention: PF sirolimus-eluting stent (PF-SES)
Number of subjects: 450
Study 22431239 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer paclitaxel-eluting stent (PES)
Number of subjects: 450
Study 21555967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 3 consecutive injections of 1.25 mg given 6 weeks apart.
Number of subjects: 115
Study 21555967 — intervention group
Group type: COMPARATOR
Intervention: Combined intravitreal bevacizumab and triamcinolone (IVB/IVT) - first injection combined with 2 mg of triamcinolone.
Number of subjects: 115
Study 21555967 — intervention group
Group type: COMPARATOR
Intervention: IVB/IVT group
Number of subjects: 115
Study 19215749 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical model with risk assessment and management strategies for caries prevention and management
Number of subjects: 0
Study 18077838 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 0
Study 18077838 — intervention group
Group type: COMPARATOR
Intervention: Short-course antenatal zidovudine
Number of subjects: 0
Study 18077838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine use
Number of subjects: 0
Study 15378428 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 69
Study 15378428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 69
Study 15378428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11223703 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM patients (hyper-, normo-, hypoinsulinemic)
Number of subjects: 22
Study 11223703 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM patients (hypo- and normoinsulinemic)
Number of subjects: 22
Study 11223703 — intervention group
Group type: COMPARATOR
Intervention: Normo- and hypoinsulinemic GDM patients
Number of subjects: 22
Study 11223703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic GDM patients
Number of subjects: 22
Study 9620242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (accelerated)
Number of subjects: 0
Study 9620242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Number of subjects: 0
Study 7979117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ketamine by subcutaneous infusion (0.1 mg.kg‐1.h‐1)
Number of subjects: 60
Study 7979117 — intervention group
Group type: COMPARATOR
Intervention: Morphine by subcutaneous infusion (0.03 mg.kg‐1.h‐1)
Number of subjects: 60
Study 2532383 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 2532383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 12
Study 2532383 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol after Ipratropium
Number of subjects: 12
Study 2532383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium after Salbutamol
Number of subjects: 12
Study 989373 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Amphetamine
Number of subjects: 0
Study 989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoridazine
Number of subjects: 0
Study 989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study 989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin
Number of subjects: 0
Study 30506499 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields plus temozolomide (TTFields/TMZ)
Number of subjects: 0
Study 30506499 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study 27796647 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of piperacillin/tazobactam (4/0.5 g over 3 hours every 6 hours)
Number of subjects: 50
Study 27796647 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion (II) of piperacillin/tazobactam (4/0.5 g over 30 minutes)
Number of subjects: 50
Study 27796647 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI)
Number of subjects: 50
Study 27796647 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion (II)
Number of subjects: 50